# Clinical Trial Scheme of Tanreqing Capsules in the Treatment of COVID-19

> **NCT05305456** · PHASE3 · COMPLETED · sponsor: **Jiangsu Famous Medical Technology Co., Ltd.** · enrollment: 480 (actual)

## Conditions studied

- Novel Coronavirus Pneumonia

## Interventions

- **DRUG:** Tanreqing capsule
- **DRUG:** Tanreqing capsule simulator

## Key facts

- **NCT ID:** NCT05305456
- **Lead sponsor:** Jiangsu Famous Medical Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-28
- **Primary completion:** 2022-06-02
- **Final completion:** 2022-08-31
- **Target enrollment:** 480 (ACTUAL)
- **Last updated:** 2022-12-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05305456

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05305456, "Clinical Trial Scheme of Tanreqing Capsules in the Treatment of COVID-19". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05305456. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*